Jonathan Cheah to Patient Reported Outcome Measures
This is a "connection" page, showing publications Jonathan Cheah has written about Patient Reported Outcome Measures.
Connection Strength
0.338
-
Cheah JTL, Robson JC, Black RJ, Goodman SM, Lester S, Mackie SL, Hill CL. The patient's perspective of the adverse effects of glucocorticoid use: A systematic review of quantitative and qualitative studies. From an OMERACT working group. Semin Arthritis Rheum. 2020 10; 50(5):996-1005.
Score: 0.153
-
Cheah JTL, Black RJ, Robson JC, Navarro-Mill?n IY, Young SR, Richards P, Beard S, Simon LS, Goodman SM, Mackie SL, Hill CL. Toward a Core Domain Set for Glucocorticoid Impact in Inflammatory Rheumatic Diseases: The OMERACT 2018 Glucocorticoid Impact Working Group. J Rheumatol. 2019 09; 46(9):1179-1182.
Score: 0.138
-
Bridgewater S, Shepherd MA, Dawson J, Richards P, Silverthorne C, Ndosi M, Almeida C, Black RJ, Cheah JTL, Dures E, Ghosh N, Hoon EA, Lyne S, Navarro-Millan I, Pearce-Fisher D, Ruediger C, Tieu J, Yip K, Mackie SL, Goodman S, Hill C, Robson JC. Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: international development of a glucocorticoid treatment-specific patient-reported outcome measure. Rheumatology (Oxford). 2023 11 02; 62(11):3565-3575.
Score: 0.048